Cerapedics Revenue and Competitors

Denver, CO USA



Total Funding



Estimated Revenue & Valuation

  • Cerapedics's estimated annual revenue is currently $49.2M per year.(i)
  • Cerapedics received $22.0M in venture funding in July 2018.
  • Cerapedics's estimated revenue per employee is $193,750
  • Cerapedics's total funding is $180.7M.

Employee Data

  • Cerapedics has 254 Employees.(i)
  • Cerapedics grew their employee count by 15% last year.

Cerapedics's People

CEOReveal Email/Phone
Area VPReveal Email/Phone
Area VPReveal Email/Phone
Area VPReveal Email/Phone
CEOReveal Email/Phone
CEOReveal Email/Phone
General CounselReveal Email/Phone
VP Strategy, Marketing & AnalyticsReveal Email/Phone
VP RegulatoryReveal Email/Phone
VP Clinical & Market DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Cerapedics?

Cerapedics is an advanced orthobiologics company focused on developing its proprietary biomimetic small peptide molecule (P-15) for commercialization in spinal applications. i-FACTOR Peptide Enhanced Bone Graft (P-15/ABM) is only the 2nd FDA PMA Approve bone graft on the market, and it has shown statistical superiority to local autograft through an IDE trial on single-level ACDFs in overall clinical success at one year. i-FACTOR is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action (Attract, Attach, Activate) is designed to support safer and more predictable bone formation compared to other commercially available bone growth factors.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Cerapedics News

2022-03-22 - PMA Fusion Bone Graft 70x More Economical than Autograft

Cerapedics describes i-FACTOR as a peptide enhanced bone graft that will “Attract, Attach, and Activate” osteogenic cells to build bone...

2021-08-17 - Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery

WESTMINSTER, Colo., Aug. 17, 2021 /PRNewswire/ -- Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for p ...

2021-04-29 - Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease

WESTMINSTER, Colo., April 29, 2021 /PRNewswire/ -- Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graf ...

2020-11-05 - Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ -- Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. "We are excited to ...

2019-07-09 - Cerapedics Expands Headquarters in Denver, Colorado Area

Cerapedics, a private ortho-biologics company, plans an expansion of the company's headquarters located in metro Denver, Colorado.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Cerapedics Funding

DateAmountRoundLead InvestorsReference
2012-12-13$19.0MCMedImmune Ventures, CVF LLCArticle
2014-04-15$9.0MUndisclosedGE CapitalArticle
2015-04-08$8.0MUndisclosedGE CapitalArticle
2017-04-20$20.0MUndisclosedOxford FinanceArticle
2018-07-16$22.0MUndisclosedKCK GroupArticle